Healthquad, India’s leading specialist healthcare focused venture capital fund, has achieved its final close with total commitment of Rs. 75 crore for investing in thematic and disruptive healthcare business models in India. The Fund is also the first early stage investment vehicle by the leading healthcare private equity investors, Dr. Amit Varma, Abrar Mir and Charles Antione Janssen.
The Fund targets to invest around Rs. 400 crore in healthcare companies that have the potential to disrupt the healthcare landscape by dramatically improving the productivity, affordability and accessibility of healthcare through differentiated and innovative solutions.
The Fund’s investment strategy targets five key healthcare sub-sectors including Healthcare Delivery Services, Life-Sciences, Medical Devices & Technology, Healthcare IT and Associated Healthcare Services. It is looking to invest in 8-10 companies. Prior to its final close, the Fund has already made investment in four companies including the recently announced investment in Regency Healthcare.
Fund’s sponsor Dr Amit Varmasaid said “Healthcare sector has seen emergence of over 500 startups in the last two years and venture capital firms have infused around Rs. 25 billion. We are looking to deploy around Rs. 4 billion, along with co-investors and partner funds in healthcare models that are driven by new age disruptive technology and are changing the way healthcare is delivered and accessed in India.”
Fund’s co-sponsor and his colleague Abrar Mir, added: “Our deployments in healthcare across sub-sectors and geographies provide extensive synergies to help companies scale-up rapidly and that forms the basis of our compelling proposition to healthcare entrepreneurs in India.”
Lastly, Charles Antione Janssen, Fund’s third co-sponsor added: “Our first four Healthquad investments have confirmed that business model innovations and health tech innovations will open access to quality healthcare for hundreds of millions of neglected Indians. Our final close will allow us to fund more, fast growing, profitable and highly impactful companies. We look forward to supporting great entrepreneurs for the benefit of patients as well as our LPs.”